Russell W Blacher

7160862, Jan 9, 2007

Jan 24, 2005

11/042492

Yoshinari Kumagai - Hayward CA, US
Toshiyuki Yoneda - San Antonio TX, US
Russell Wayne Blacher - Hayward CA, US
Motoyoshi Nomizu - Tokyo, JP

Acologix, Inc. - Hayward CA

A61K 38/00
C07K 11/00
C07K 14/00

514 12, 514 14, 514 15, 530300, 530324, 530325, 530326, 530327, 530334, 530344, 435 691, 424 91

Peptide sequences comprising 10 to 50 amino acids are disclosed. The sequences are characterized by containing at least one of an integrin binding motif such as an RGD sequence, a glycosaminoglycan binding motif, and a calcium binding motif, and the remainder of amino acids contiguous with the RGD sequence in matrix extracellular phosphoglycoprotein. The sequences may be formulated for injection or dispersed in toothpaste or a mouthwash or gum patch and administered to enhance bone/tooth growth and/or reduce excessive urinary phosphate loss from the body.

7498021, Mar 3, 2009

Apr 19, 2006

11/379316

Toshiyuki Yoneda - San Antonio TX, US
Motoyoshi Nomizu - Tokyo, JP
Yoshinari Kumagai - Hayward CA, US
Russell Wayne Blacher - Hayward CA, US

Acologix, Inc. - Hayward CA

A61K 7/16
A61K 38/00
C07K 17/00

424 49, 424 50, 530324, 530326, 530328, 530350, 514 2, 514 7, 514 8, 514 12, 514 14, 514899, 514901

Dental products such as toothpastes, mouthwash and dental floss are disclosed which products are enhanced by having dissolved, dispersed or coated thereon a compound which promoted bone growth. Preferred compounds are peptide sequences comprising 10 to 50 amino acids are disclosed. The sequences are characterized by containing an integrin binding motif such as RGD sequence and the remainder of amino acids contiguous with the RGD sequence in matrix extracellular phosphoglycoprotein. The sequences may be formulated for dispersed in toothpaste or a mouthwash and administered to enhance bone/tooth growth. When the dental products are used repeatedly over time they enhance good dental health.

7879805, Feb 1, 2011

May 29, 2008

12/129504

Dennis Chen - Milbrae CA, US
Russell Wayne Blacher - Castro Valley CA, US
Byeong Chang - Hayward CA, US

Acologix, Inc. - Emeryville CA

A61K 38/16

514 214, 53612313, 424489

A stabilized pharmaceutical composition in the form of a lyophilized product to be later reconstituted to generate an aqueous drug product is described herein. The therapeutically active ingredient in the form of a peptide of sequence TDLQERGDNDISPFSGDGQPFKD is stabilized with a buffer, carbohydrate stabilizer, a nonionic bulking agent and a surfactant to facilitate reconstitution. The preferred preparation contains a peptide of the sequence TDLQERGDNDISPFSGDGQPFKD, histidine buffer, mannitol or glycine, sucrose and/or Polysorbate 20. This combination of excipients has demonstrated exceptional stability as a lyophilized product when stored at the elevated temperature of 40 C. for at least 6 months and for at least 3 Months at 50 C. The lyophilized mixture thus formed is reconstituted to a high peptide concentration without apparent loss of stability of the peptide. Also, this combination of excipients has also enabled the ability to terminally sterilize the lyophilized product using gamma irradiation without affecting the stability of the active ingredient of the formulation.

20020197267, Dec 26, 2002

Mar 19, 2001

09/812485

Yoshinari Kumagai - Austin TX, US
Toshiyuki Yoneda - San Antonio TX, US
Russell Blacher - Castro Valley CA, US

A61K039/00
C07K014/435

424/185100, 530/324000, 530/326000, 530/327000

Peptide sequences comprising 10 to 50 amino acids are disclosed. The sequences are characterized by containing at least one of an integrin binding motif such as an RGD sequence, a glycosaminoglycan binding motif, and a calcium binding motif, and the remainder of amino acids contiguous with the RGD sequence in matrix extracellular phosphoglycoprotein. The sequences may be formulated for injection or dispersed in toothpaste or a mouthwash or gum patch and administered to enhance bone/tooth growth and/or reduce excessive urinary phosphate loss from the body.

20030186891, Oct 2, 2003

Feb 7, 2003

10/360202

Toshio Okano - Kobe, JP
Naoko Tsugawa - Kobe, JP
Kimie Nakagawa - Kobe, JP
Russell Blacher - Castro Valley CA, US
Yoshinari Kumagai - Alameda CA, US

A61K038/10
C07K007/08

514/014000, 530/326000

The present invention provides peptides which are characterized by having a biological activity that increases 25-hydroxyvitamin D3 1-hydroxylase activity in a cell, thereby increasing calcitriol (active vitamin D) levels. The peptides have a sequence related to the contiguous sequence defined by residues 242 to 264 in the naturally occurring matrix extracellular phosphoglycoprotein (PHEX). Methods of modulating 25-hydroxyvitamin 1-hydroxylase gene expression and calcitriol levels using the subject peptides are also provided. Also provided are kits for practicing the subject methods. The subject compositions and methods find use in a variety of application, including the treatment of vitamin D-related disorders, such as Paget's Disease, rickets, osteoporosis, renal osteodystrophy, and psoriasis.

20060104974, May 18, 2006

Feb 15, 2001

09/784950

C. Davis - Burlingame CA, US
Russell Blacher - Castro Valley CA, US
Jose Corvalan - Foster City CA, US
Alan Culwell - Carlsbad CA, US
Larry Green - San Francisco CA, US
Joanne Hales - Fremont CA, US
Nancy Havrilla - Oakland CA, US
Vladimir Ivanov - Fremont CA, US
John Lipani - Livermore CA, US
Qiang Liu - Foster City CA, US
Richard Weber - San Francisco CA, US
Xiao-Dong Yang - Palo Alto CA, US

A61K 39/395
C07K 16/28

424144100, 530388220

In accordance with the present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies that bind to CD147 and that result in the killing of such cells, for example, through the binding of complement, is efficacious in the treatment of diseases. Diseases in which such treatment appears efficacious include, without limitation: graft versus host disease (GVHD), organ transplant rejection diseases (including, without limitation, renal transplant, ocular transplant, and others), cancers (including, without limitation, cancers of the blood (i.e., leukemias and lymphomas), pancreatic, and others), autoimmune diseases, inflammatory diseases, and others.

20070014742, Jan 18, 2007

Sep 13, 2006

11/531583

Yoshinari Kumagai - Hayward CA, US
Toshiyuki Yoneda - San Antonio TX, US
Russell Blacher - Hayward CA, US
Motoyoshi Nomizu - Tokyo, JP

A61K 38/10
A61K 38/06
A61K 8/66

424050000, 514014000, 514018000

Peptide sequences comprising 10 to 50 amino acids are disclosed. The sequences are characterized by containing at least one of an integrin binding motif such as an RGD sequence, a glycosaminoglycan binding motif, and a calcium binding motif, and the remainder of amino acids contiguous with the RGD sequence in matrix extracellular phosphoglycoprotein. The sequences may be formulated for injection or dispersed in toothpaste or a mouthwash or gum patch and administered to enhance bone/tooth growth and/or reduce excessive urinary phosphate loss from the body.

20070048305, Mar 1, 2007

Feb 28, 2006

11/366003

C. Davis - Burlingame CA, US
Russell Blacher - Castro Valley CA, US
Jose Corvalan - Foster City CA, US
Alan Culwell - Carlsbad CA, US
Larry Green - San Francisco CA, US
Joanna Hales - Fremont CA, US
Nancy Havrilla - Oakland CA, US
Vladimir Ivanov - Fremont CA, US
John Lipani - Livermore CA, US
Qiang Liu - Foster CA, US
Richard Weber - San Francisco CA, US
Xiao-Dong Yang - Palo Alto CA, US

A61K 39/395
C07K 16/28

424144100, 530388220

In accordance with the present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies that bind to CD147 and that result in the killing of such cells, for example, through the binding of complement, is efficacious in the treatment of diseases. Diseases in which such treatment appears efficacious include, without limitation: graft versus host disease (GVHD), organ transplant rejection diseases (including, without limitation, renal transplant, ocular transplant, and others), cancers (including, without limitation, cancers of the blood (i.e., leukemias and lymphomas), pancreatic, and others), autoimmune diseases, inflammatory diseases, and others.